NORML
JANUARY 28, 2019
The New York State Association of Police said traffic safety is a major concern, citing an increase in vehicle-related fatalities by 62 percent in Colorado the first year cannabis was legalized in the state. 2 years before medical legalization, the largest number of vehicle-related fatalities in the last 17 years. Sales began January 1.
Cannabis Law Report
OCTOBER 29, 2019
ElleVet Sciences is pleased to announce the results and publication of the first safety study on the use of hemp CBD/CBDA. The 12-week safety study, conducted by Dr. Joseph Wakshlag, DVM, Ph.D., This data gives us confidence in the use of both the chew and the oils as effective means for delivering CBD to your pet.”.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
JANUARY 23, 2022
ciency illnesses, congenital metabolic defects, hemoglobinopathies, and myelodysplastic and myeloproliferative syndromes (Weisdorf, 2007). GVHD is currently managed with a host of immune-suppressing drugs that support the body’s uptake of the donated tissue (Shlomchik, 2007). 2007) ‘GVHD—The Nuts and Bolts’, Hematology.
Cannabis Law Report
FEBRUARY 2, 2022
CLARA uses natural language processing to perform contextual analysis, incorporating structured, semi-structured and unstructured data into its AI analysis. The National Highway Traffic Safety Administration (NHTSA) reports that the percentage of fatally injured drivers who tested positive for drugs increased from 25% in 2007 to 42% in 2016.
Cannabis Law Report
MAY 26, 2022
was published in the Journal of Safety Research and made available online on May 18. Journal of Safety Research. 2007, Shults et al., All data collection was completed prior to the COVID-19 pandemic. The two data collection teams were able to collect data at 47 of the 50 retail outlets. 2001, Voas et al.,
Cannabis Law Report
APRIL 8, 2022
The FDA formally decided to open the door to psychedelic research in human participants, and later accepted MAPS’ Phase 1 MDMA safety and tolerance study protocol. MAPS completed the first Phase 1 safety study with MDMA and resumed working on a protocol for anxiety associated with cancer. Rick Doblin, Ph.D.,
Greencamp
APRIL 23, 2019
In 2005, a group of researchers was looking into the effectiveness and long-term safety of tetrahydrocannabinol for MS. Cannabis for Lupus: Here’s How Cannabinoids Relieve Inflammation. Using cannabis to treat general symptoms of MS. During a 15-week period, 630 patients with a stable form of MS were given THC or placebo.
Expert insights. Personalized for you.
186 
Let's personalize your content